191 related articles for article (PubMed ID: 33227576)
1. Application of sulfoximines in medicinal chemistry from 2013 to 2020.
Han Y; Xing K; Zhang J; Tong T; Shi Y; Cao H; Yu H; Zhang Y; Liu D; Zhao L
Eur J Med Chem; 2021 Jan; 209():112885. PubMed ID: 33227576
[TBL] [Abstract][Full Text] [Related]
2. Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and in vitro Parameters Relevant for Drug Discovery.
Frings M; Bolm C; Blum A; Gnamm C
Eur J Med Chem; 2017 Jan; 126():225-245. PubMed ID: 27821325
[TBL] [Abstract][Full Text] [Related]
3. Sulfoximines: a neglected opportunity in medicinal chemistry.
Lücking U
Angew Chem Int Ed Engl; 2013 Sep; 52(36):9399-408. PubMed ID: 23934828
[TBL] [Abstract][Full Text] [Related]
4. Sulfur Containing Scaffolds in Drugs: Synthesis and Application in Medicinal Chemistry.
Feng M; Tang B; Liang SH; Jiang X
Curr Top Med Chem; 2016; 16(11):1200-16. PubMed ID: 26369815
[TBL] [Abstract][Full Text] [Related]
5. Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.
Foote KM; Nissink JWM; McGuire T; Turner P; Guichard S; Yates JWT; Lau A; Blades K; Heathcote D; Odedra R; Wilkinson G; Wilson Z; Wood CM; Jewsbury PJ
J Med Chem; 2018 Nov; 61(22):9889-9907. PubMed ID: 30346772
[TBL] [Abstract][Full Text] [Related]
6. Sulfoximines as potent RORγ inverse agonists.
Ouvry G; Bihl F; Bouix-Peter C; Christin O; Defoin-Platel C; Deret S; Feret C; Froude D; Hacini-Rachinel F; Harris CS; Hervouet C; Lafitte G; Luzy AP; Musicki B; Orfila D; Parnet V; Pascau C; Pascau J; Pierre R; Raffin C; Rossio P; Spiesse D; Taquet N; Thoreau E; Vatinel R; Vial E; Hennequin LF
Bioorg Med Chem Lett; 2018 May; 28(8):1269-1273. PubMed ID: 29571573
[TBL] [Abstract][Full Text] [Related]
7. Increasing Complexity: A Practical Synthetic Approach to Three-Dimensional, Cyclic Sulfoximines and First Insights into Their in Vitro Properties.
Boulard E; Zibulski V; Oertel L; Lienau P; Schäfer M; Ganzer U; Lücking U
Chemistry; 2020 Apr; 26(19):4378-4388. PubMed ID: 31961028
[TBL] [Abstract][Full Text] [Related]
8. Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates.
Sirvent JA; Lücking U
ChemMedChem; 2017 Apr; 12(7):487-501. PubMed ID: 28221724
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of tert-butyl isosteres: case studies of physicochemical and pharmacokinetic properties, efficacies, and activities.
Westphal MV; Wolfstädter BT; Plancher JM; Gatfield J; Carreira EM
ChemMedChem; 2015 Mar; 10(3):461-9. PubMed ID: 25630804
[TBL] [Abstract][Full Text] [Related]
10. Rhodium-catalyzed direct synthesis of unprotected NH-sulfoximines from sulfoxides.
Miao J; Richards NG; Ge H
Chem Commun (Camb); 2014 Sep; 50(68):9687-9. PubMed ID: 25016917
[TBL] [Abstract][Full Text] [Related]
11. Iron(II) triflate as an efficient catalyst for the imination of sulfoxides.
Mancheño OG; Dallimore J; Plant A; Bolm C
Org Lett; 2009 Jun; 11(11):2429-32. PubMed ID: 19473047
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of Sulfoximine Carbamates by Rhodium-Catalyzed Nitrene Transfer of Carbamates to Sulfoxides.
Zenzola M; Doran R; Luisi R; Bull JA
J Org Chem; 2015 Jun; 80(12):6391-9. PubMed ID: 25989821
[TBL] [Abstract][Full Text] [Related]
13. Sulfoximines as Rising Stars in Modern Drug Discovery? Current Status and Perspective on an Emerging Functional Group in Medicinal Chemistry.
Mäder P; Kattner L
J Med Chem; 2020 Dec; 63(23):14243-14275. PubMed ID: 32870008
[TBL] [Abstract][Full Text] [Related]
14. New Opportunities for the Utilization of the Sulfoximine Group in Medicinal Chemistry from the Drug Designer's Perspective.
Lücking U
Chemistry; 2022 Oct; 28(56):e202201993. PubMed ID: 35789054
[TBL] [Abstract][Full Text] [Related]
15. The Discovery of Macitentan - A Standard Medicinal Chemistry Program?
Bolli MH
Chimia (Aarau); 2017 Aug; 71(7):420-429. PubMed ID: 28779766
[TBL] [Abstract][Full Text] [Related]
16. BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application.
Siemeister G; Lücking U; Wengner AM; Lienau P; Steinke W; Schatz C; Mumberg D; Ziegelbauer K
Mol Cancer Ther; 2012 Oct; 11(10):2265-73. PubMed ID: 22821149
[TBL] [Abstract][Full Text] [Related]
17. Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.
Jiang JK; Huang X; Shamim K; Patel PR; Lee A; Wang AQ; Nguyen K; Tawa G; Cuny GD; Yu PB; Zheng W; Xu X; Sanderson P; Huang W
Bioorg Med Chem Lett; 2018 Nov; 28(20):3356-3362. PubMed ID: 30227946
[TBL] [Abstract][Full Text] [Related]
18. Sulfoxaflor and the sulfoximine insecticides: chemistry, mode of action and basis for efficacy on resistant insects.
Sparks TC; Watson GB; Loso MR; Geng C; Babcock JM; Thomas JD
Pestic Biochem Physiol; 2013 Sep; 107(1):1-7. PubMed ID: 25149228
[TBL] [Abstract][Full Text] [Related]
19. The lab oddity prevails: discovery of pan-CDK inhibitor (R)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the treatment of cancer.
Lücking U; Jautelat R; Krüger M; Brumby T; Lienau P; Schäfer M; Briem H; Schulze J; Hillisch A; Reichel A; Wengner AM; Siemeister G
ChemMedChem; 2013 Jul; 8(7):1067-85. PubMed ID: 23671017
[TBL] [Abstract][Full Text] [Related]
20. Expedition of in vitro dissolution and in vivo pharmacokinetic profiling of sulfur nanoparticles based antimicrobials.
Choudhury SR; Basu A; Nag T; Sengupta K; Bhowmik M; Goswami A
Environ Toxicol Pharmacol; 2013 Sep; 36(2):675-679. PubMed ID: 23892072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
